Related Experiment Video

Updated: Jul 3, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Bcl-2 family members as molecular targets in cancer therapy

Isabel Marzo1, Javier Naval

  • 1Departamento de Bioquimica y Biologia Molecular y Celular, Facultad de Ciencias, Universidad de Zaragoza, Pedro Cerbuna, 12, 50009 Zaragoza, Spain. imarzo@unizar.es

Biochemical Pharmacology
|July 22, 2008
PubMed

Insights

Cancer cells evade apoptosis, leading to drug resistance. Targeting Bcl-2 proteins offers a promising strategy for developing new anticancer therapies by restoring the cell death pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer cells frequently evade apoptosis, contributing to chemotherapy resistance and tumor recurrence.
  • The Bcl-2 protein family critically regulates the intrinsic apoptosis pathway, controlling cell death thresholds.
  • Bcl-2 proteins are key targets for novel anticancer drug development.

Purpose of the Study:

  • To review recent advancements in Bcl-2 targeted anticancer therapies.
  • To highlight the role of Bcl-2 proteins in apoptosis and cancer.
  • To discuss strategies for neutralizing antiapoptotic Bcl-2 proteins.

Main Methods:

  • Literature review of recent research on Bcl-2 targeted therapies.
  • Analysis of pharmacological approaches including peptides, small molecules, and oligonucleotides.
  • Discussion of mechanisms to lower apoptosis threshold in cancer cells.

Main Results:

  • Bcl-2 proteins are crucial regulators of apoptosis.
  • Targeting Bcl-2 proteins can restore apoptosis in cancer cells.
  • Various therapeutic strategies are being developed to inhibit antiapoptotic Bcl-2 proteins.

Conclusions:

  • Developing drugs targeting Bcl-2 proteins is a promising strategy for cancer treatment.
  • Neutralizing antiapoptotic Bcl-2 proteins can overcome chemotherapy resistance.
  • Recent advances show potential for novel Bcl-2-based anticancer therapies.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...